They’ve been studying the same group of people for 76 years. This is what they’ve learned about Alzheimer’s disease… so far. Psychology in epidemiology…
In Phase 3 trials, Roche’s experimental Alzheimer’s drug gantenerumab has failed to meet its objectives for slowing cognitive decline. Most Alzheimer’s treatments on the market…
Some of the most common treatments for Alzheimer’s symptoms may be prescribed in pill form, as an oral solution, or even as a transdermal…
As the Biden administration rings in National Alzheimer’s Awareness Month, American voters in the midterm elections stand to decide whether prescription drug prices will…
Despite a doctor’s racist stereotypes, myriad financial crises and 16 years helping her mother live well with dementia, caregiver Loretta Veney shows up with…
Researchers in Tokyo continue encouraging research on oxytocin as a potential Alzheimer’s drug target. When administered nasally, the hormone appeared to reverse cognitive decline…
In June, a patient enrolled in the Phase 3 clinical trial for experimental Alzheimer’s drug lecanemab experienced brain bleeds and later died. It is…